Efficacy and Safety of Once-Daily Controlled-Release Pregabalin for the Treatment of Patients With Postherpetic Neuralgia: A Double-Blind, Enriched Enrollment Randomized Withdrawal, Placebo-Controlled Trial

普瑞巴林 疱疹后神经痛 医学 麻醉 药理学 神经病理性疼痛
作者
Cynthia Huffman,James N. Goldenberg,James Weintraub,Luis C. Sanin,Joseph Driscoll,Ruoyong Yang,Marci L. Chew,Joseph M. Scavone
出处
期刊:The Clinical Journal of Pain [Lippincott Williams & Wilkins]
卷期号:33 (7): 569-578 被引量:26
标识
DOI:10.1097/ajp.0000000000000445
摘要

OBJECTIVES: To assess efficacy and safety of once-daily controlled-release (CR) formulation of pregabalin in patients with postherpetic neuralgia. METHODS: An enriched enrollment, randomized withdrawal trial, with 6-week single-blind pregabalin treatment phase and 13-week double-blind phase, where patients with ≥50% decrease in mean pain score at single-blind end point from baseline were randomized (1:1) to pregabalin CR (82.5 to 660 mg/d) or placebo. Primary efficacy outcome was time to loss of therapeutic response (LTR) (<30% decrease in weekly mean pain score from single-blind baseline or discontinuation due to adverse event or lack of efficacy). Secondary efficacy outcomes included change in weekly mean pain score (1-wk recall period) at double-blind end point. RESULTS: In total, 801 patients were randomized and treated in the single-blind phase, and 413 in the double-blind phase (208, pregabalin CR; 205, placebo). Pregabalin CR significantly increased time to LTR versus placebo (Kaplan-Meier analysis) with significantly fewer LTR events with pregabalin CR than with placebo (29 [13.9%] vs. 63 [30.7%]; P<0.0001). Median time to LTR was not estimable. Pregabalin CR significantly improved weekly mean pain score versus placebo: LS mean difference (95% CI) of -1.11 (-1.47, -0.75) and -1.00 (-1.34, -0.65) (P<0.0001) from single-blind baseline and double-blind baseline, respectively. Most commonly reported adverse events in the single-blind phase were dizziness, somnolence, and peripheral edema. Pregabalin CR was well tolerated. DISCUSSION: Time to LTR was significantly longer with pregabalin CR than with placebo. Safety profile of pregabalin CR was comparable to that reported for the immediate-release formulation in patients with postherpetic neuralgia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_VZG7GZ的应助被张远幸采纳,获得10
1秒前
1秒前
嘟嘟完成签到,获得积分10
3秒前
领导范儿的应助被777采纳,获得10
3秒前
吴境完成签到,获得积分20
3秒前
科研通AI6.3的应助被静候灵归采纳,获得10
5秒前
5秒前
mm发布了新的文献求助10
5秒前
科研通AI2S的应助被zyy采纳,获得10
5秒前
如意的雅蕊完成签到,获得积分10
5秒前
科研通AI2S的应助被嘟嘟采纳,获得10
6秒前
科研通AI6.4的应助被obcx采纳,获得10
6秒前
草草完成签到 ,获得积分10
6秒前
在水一方的应助被初景采纳,获得10
7秒前
nn完成签到 ,获得积分10
7秒前
顾矜的应助被rainbow采纳,获得30
8秒前
TYH完成签到,获得积分10
8秒前
小马甲的应助被我们去哪li采纳,获得10
8秒前
linaoctcn完成签到,获得积分10
9秒前
虚心八宝粥完成签到,获得积分10
9秒前
英俊的铭的应助被科研通管家采纳,获得10
9秒前
9秒前
搜集达人的应助被科研通管家采纳,获得10
9秒前
niu完成签到,获得积分10
9秒前
852的应助被科研通管家采纳,获得10
9秒前
9秒前
9秒前
852的应助被科研通管家采纳,获得10
10秒前
ding的应助被科研通管家采纳,获得10
10秒前
hope完成签到 ,获得积分10
10秒前
李健的应助被科研通管家采纳,获得10
10秒前
缺粥发布了新的文献求助10
10秒前
Hello的应助被科研通管家采纳,获得10
10秒前
10秒前
wanci的应助被科研通管家采纳,获得30
10秒前
10秒前
范晓圳完成签到 ,获得积分10
10秒前
10秒前
wanci的应助被科研通管家采纳,获得10
10秒前
Youdge的应助被科研通管家采纳,获得20
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187362
求助须知:如何正确求助?哪些是违规求助? 9575478
关于积分的说明 21841431
捐赠科研通 7785067
什么是DOI,文献DOI怎么找? 3434943
关于科研通互助平台的介绍 2559401
邀请新用户注册赠送积分活动 2481820